Intermediatebiotechnology
Gene Therapy
Overview
Gene therapy treats disease by delivering genetic material: replacing defective genes (Luxturna for RPE65 blindness), adding functional copies (Zolgensma for SMA), or editing in place (Casgevy). Vectors include AAV (non-integrating, tissue-tropic serotypes), lentiviruses (integrating, ex vivo), and lipid nanoparticles (mRNA). After early setbacks (1999 Gelsinger tragedy), the field now has 10+ approved products.
Learning objectives
- Define gene therapy strategies
- Compare AAV, lentiviral, and LNP delivery
- Name approved therapies and their mechanisms
- Describe safety lessons and challenges
Strategies
Gene replacement/addition: deliver a working copy (doesn't remove the mutant). Gene editing: correct in place (CRISPR). Gene silencing: shRNA/siRNA knockdown. Cell therapies (CAR-T) engineer cells with new genes: sometimes classed separately, mechanistically gene therapy.
Three strategies cover most monogenic diseases and beyond.
Delivery vehicles
AAV: small (~4.7 kb capacity), non-integrating, serotypes target liver/eye/muscle/CNS; pre-existing immunity limits redosing. Lentivirus: integrates (stable, ex vivo HSC therapies like betibeglogene). LNPs: deliver mRNA transiently (COVID vaccines proved the platform; in vivo CRISPR via LNP in trials).
4.7 kb capsids exclude big genes (dystrophin needs mini-versions): packaging constrains design.
Approved therapies
Luxturna (2017): AAV-RPE65 for inherited blindness. Zolgensma: AAV-SMN1 for spinal muscular atrophy (~$2M, one-time). Hemgenix/Roctavian: hemophilia A/B. Casgevy/Lyfgenia: sickle cell. CAR-Ts (Kymriah, Yescarta): engineered T cells curing some leukemias/lymphomas.
Million-dollar one-time prices strain health systems: cures exist that societies can't afford to deliver.
Safety lessons
1999: Jesse Gelsinger died from adenoviral vector immune response, freezing the field. Early retroviral trials caused leukemia via insertional mutagenesis. Modern designs (self-inactivating lentiviruses, tissue-specific AAV) reflect hard-won caution; long-term follow-up is mandatory.
Each tragedy rewrote vector design: the field's safety culture was built from failures.
Key points
- Strategies: gene addition, editing, silencing
- AAV (in vivo, non-integrating), lentivirus (ex vivo, integrating), LNP (mRNA)
- Approved: Luxturna, Zolgensma, hemophilia therapies, Casgevy, CAR-Ts
- Safety shaped by Gelsinger tragedy and insertional mutagenesis cases
Common misconceptions
✓ Truth: Approved therapies are somatic (or ex vivo); germline editing is not practiced or permitted.
✓ Truth: Durability varies; AAV expression can wane, and long-term data are still maturing.
Practice questions
Q1. Luxturna treats inherited blindness by
- Editing the germline
- AAV delivery of functional RPE65 to retinal cells
- Corneal transplant
- Laser surgery
Subretinal AAV supplies the missing enzyme in RPE cells.
Q2. AAV vectors are favored for in vivo therapy because they
- Integrate efficiently
- Are mostly non-integrating with tissue-specific serotypes
- Carry huge genes
- Avoid immunity
Episomal persistence without integration; serotypes target tissues.
Q3. The 1999 Gelsinger tragedy involved
- CRISPR
- A fatal immune response to an adenoviral vector
- Cloning
- Vaccines
Ornithine transcarbamylase trial: vector immunity caused multi-organ failure.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why is SMA treatable by gene therapy?
Single-gene (SMN1) loss with a backup gene (SMN2): adding SMN1 via AAV rescues motor neurons if treated early.
What limits AAV redosing?
Neutralizing antibodies from the first dose (or natural AAV exposure) block repeat administration.
How do CAR-T cells work?
Patient T cells are lentivirally engineered with chimeric antigen receptors targeting cancer, then reinfused.